An employee checks the production of chloroquine phosphate at a pharmaceutical company in Nantong city in east China's Jiangsu province, Thursday, Feb. 27, 2020. (Getty Images)
March 24, 2020 07:06 AM EDTUpdated 01:02 PM
Coronavirus

'I have a feel­ing': Trump-en­dorsed malar­ia drug fails to pass muster in small Chi­nese coro­n­avirus study

Natalie Grover

Reporter

De­spite the FDA’s re­luc­tance to en­dorse with­out de­fin­i­tive clin­i­cal tri­al da­ta the decades-old an­ti-malar­i­al drugs chloro­quine and de­riv­a­tive hy­drox­y­chloro­quine as treat­ments to com­bat the coro­n­avirus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times